Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ARS Pharmaceuticals ( (SPRY) ) has provided an update.
On August 13, 2025, ARS Pharmaceuticals received a Paragraph IV certification notice from Lupin Inc., indicating that Lupin has filed an Abbreviated New Drug Application with the FDA to produce a generic version of ARS’s neffy© nasal spray before the expiration of several patents. ARS plans to defend its patents vigorously by filing a patent infringement lawsuit against Lupin, which could delay FDA approval of Lupin’s generic product by 30 months if filed within 45 days. The outcome of this legal action remains uncertain, but it could significantly impact ARS’s market position and intellectual property rights.
The most recent analyst rating on (SPRY) stock is a Hold with a $13.50 price target. To see the full list of analyst forecasts on ARS Pharmaceuticals stock, see the SPRY Stock Forecast page.
Spark’s Take on SPRY Stock
According to Spark, TipRanks’ AI Analyst, SPRY is a Neutral.
The overall stock score of 52 reflects strong revenue growth and strategic global expansion as significant positive factors. However, the stock’s bearish technical indicators and negative valuation metrics due to profitability challenges weigh heavily on the score. The earnings call provided a positive outlook, but high SG&A expenses and prior authorization challenges remain concerns.
To see Spark’s full report on SPRY stock, click here.
More about ARS Pharmaceuticals
ARS Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing innovative drug products. Its primary product is neffy©, an epinephrine nasal spray, which is part of its market focus on intranasal epinephrine technology.
Average Trading Volume: 1,565,106
Technical Sentiment Signal: Hold
Current Market Cap: $1.37B
See more data about SPRY stock on TipRanks’ Stock Analysis page.